Detalhe da pesquisa
1.
A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response.
Clin Infect Dis
; 2024 Feb 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38305378